Picture of Schrodinger logo

SDGR Schrodinger Share Price

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+20.54%
3m+55.19%
6m+60.31%
1yr-3.31%
Volume Change (%)
10d/3m+99.86%
Price vs... (%)
52w High-9.55%
50d MA+15.6%
200d MA+23.59%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-33.14%
Return on Equity-38.58%
Operating Margin-100.85%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Schrodinger EPS forecast chart

Profile Summary

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Directors

Last Annual
December 31st, 2024
Last Interim
December 31st, 2024
Incorporated
May 22nd, 1995
Public Since
February 6th, 2020
No. of Shareholders
87
No. of Employees
891
Sector
Software & IT Services
Industry
Technology
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
73,038,393

SDGR Share Price Performance

Upcoming Events for SDGR

Q1 2025 Schrodinger Inc Earnings Release

Schrodinger Inc Annual Shareholders Meeting

Q2 2025 Schrodinger Inc Earnings Release

Similar to SDGR

Picture of Adeia logo

Adeia

us flag iconNASDAQ Global Select Market

Picture of Adobe logo

Adobe

us flag iconNASDAQ Global Select Market

Picture of Agilysys logo

Agilysys

us flag iconNASDAQ Global Select Market

Picture of Agora logo

Agora

us flag iconNASDAQ Global Select Market

Picture of Airbnb logo

Airbnb

us flag iconNASDAQ Global Select Market

FAQ